Skip to main content
. 2021 Dec 27;27(1):137. doi: 10.3390/molecules27010137

Figure 3.

Figure 3

Small molecule antagonists targeting CXCR1/2. Blocking CXCR1 or CXCR2 impairs immune suppressive cell recruitment and angiogenesis to enhance cancer therapy efficacy.